Lack of penetration of amikacin into saliva of tuberculosis patients

Eur Respir J. 2018 Jan 11;51(1):1702024. doi: 10.1183/13993003.02024-2017. Print 2018 Jan.
No abstract available

Publication types

  • Letter
  • Observational Study

MeSH terms

  • Adult
  • Amikacin / pharmacokinetics*
  • Aminoglycosides / metabolism
  • Drug Monitoring / methods
  • Female
  • Humans
  • Immunoassay / methods
  • Male
  • Middle Aged
  • Prospective Studies
  • Saliva / drug effects*
  • Saliva / metabolism
  • Treatment Outcome
  • Tuberculosis / drug therapy*

Substances

  • Aminoglycosides
  • Amikacin

Associated data

  • ClinicalTrials.gov/NCT03080012